

HRES 1154

Affirming the importance of the Orphan Drug Act, applauding its lifesaving contributions over its 35-year history, and recognizing the need to continue supporting research and development for rare diseases.

Congress: 115 (2017–2019, Ended)

Chamber: House

Policy Area: Health

Introduced: Nov 16, 2018

Current Status: Referred to the House Committee on Energy and Commerce.

Latest Action: Referred to the House Committee on Energy and Commerce. (Nov 16, 2018)

Official Text: <https://www.congress.gov/bill/115th-congress/house-resolution/1154>

Sponsor

Name: Rep. Lance, Leonard [R-NJ-7]

Party: Republican • **State:** NJ • **Chamber:** House

Cosponsors (3 total)

| Cosponsor | Party / State | Role | Date Joined |
|----------------------------------|---------------|------|--------------|
| Rep. Butterfield, G. K. [D-NC-1] | D · NC | | Nov 16, 2018 |
| Rep. Eshoo, Anna G. [D-CA-18] | D · CA | | Nov 16, 2018 |
| Rep. Carson, Andre [D-IN-7] | D · IN | | Nov 27, 2018 |

Committee Activity

| Committee | Chamber | Activity | Date |
|-------------------------------|---------|-------------|--------------|
| Energy and Commerce Committee | House | Referred To | Nov 16, 2018 |

Subjects & Policy Tags

Policy Area:

Health

Related Bills

| Bill | Relationship | Last Action |
|--------------|--------------|---|
| 115 SRES 690 | Related bill | Nov 15, 2018: Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S7055-7056) |

Summary (as of Nov 16, 2018)

Applauds the growth in research and development into new therapies for rare diseases and the resulting number of FDA-approved therapies for those living with rare diseases, and affirms the need to continue supporting such research and development.

Recognizes that significant research and development efforts and related investments are needed to develop therapies to treat and cure thousands of rare diseases for which no treatment options are currently available.

Actions Timeline

- **Nov 16, 2018:** Introduced in House
- **Nov 16, 2018:** Referred to the House Committee on Energy and Commerce.